Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Carl Zeiss Meditec AG    AFX   DE0005313704

CARL ZEISS MEDITEC AG

(AFX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Carl Zeiss Meditec : reports further growth and defines expectations for fiscal year 2018/19

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/12/2019 | 04:05am EDT

DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Half Year Results
Carl Zeiss Meditec AG reports further growth and defines expectations for fiscal year 2018/19

12-Apr-2019 / 10:03 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec AG reports further growth and defines expectations for
fiscal year 2018/19

Jena, April 12, 2019

Carl Zeiss Meditec (ISIN: DE0005313704) has grown revenues to around EUR 667 million in the first six months of fiscal year 2018/19, based on preliminary data. This corresponds to a growth rate of approx. 9% against the previous year's value of EUR 613.7 million. Adjusted for currency effects, the growth rate was around 7%.

Carl Zeiss Meditec now further defines its expectations for the full year 2018/19: Revenue is expected to reach between EUR 1,350 million and EUR 1,420 million (previous year:
EUR 1,280.9 million).

Earnings before interest and taxes (EBIT) are expected to rise significantly in the first half
of 2018/19 to a level of around EUR 110 million (previous year: EUR 88.2 million). EBIT margin (EBIT as a % of revenue) will amount to around 16.5% in the first half of 2018/19 (previous year: 14.4%). The increase was supported by a positive trend in product mix with a high share of recurring revenue, in particular.

In light of these developments, Carl Zeiss Meditec raises the expectation for full year EBIT margin. EBIT margin is now expected to reach a corridor of 15.0% - 17.5% (previously: 14.0% - 16.0%). EBIT margin had amounted to 15.4% in the previous year 2017/18.

The six months 2018/19 financial report will be published on May 6, 2019.
 


Contact for investors and press
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: investors.meditec@zeiss.com


12-Apr-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.meditec@zeiss.com
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 799331

 
End of Announcement DGAP News Service

799331  12-Apr-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=799331&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARL ZEISS MEDITEC AG
05/06GLOBAL MARKETS LIVE : Boeing, Berkshire Hathaway, Airbus, Occidental Petroleum…
05/06CARL ZEISS MEDITEC : First half year 2018/2019: Continued profitable growth for ..
PU
05/06CARL ZEISS MEDITEC : Continued profitable growth for Carl Zeiss Meditec
EQ
04/29CARL ZEISS MEDITEC : ZEISS PLEX Elite 2.0 at ARVO
AQ
04/29CARL ZEISS MEDITEC AG : Preliminary announcement of the publication of financial..
EQ
04/12European shares end higher boosted by banks and auto stocks
RE
04/12CARL ZEISS MEDITEC : reports further growth and defines expectations for fiscal ..
EQ
04/04Medical Imaging Workstations Market 2026 Trends, Top Companies - Ampronix, Ca..
AQ
03/20CARL ZEISS MEDITEC : Ex-dividend day for final dividend
FA
03/11CARL ZEISS MEDITEC : FDA Clearance for Epithelial Thickness Mapping
AQ
More news
Financials (€)
Sales 2019 1 410 M
EBIT 2019 235 M
Net income 2019 162 M
Finance 2019 658 M
Yield 2019 0,70%
P/E ratio 2019 49,60
P/E ratio 2020 41,80
EV / Sales 2019 5,12x
EV / Sales 2020 4,64x
Capitalization 7 880 M
Chart CARL ZEISS MEDITEC AG
Duration : Period :
Carl Zeiss Meditec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARL ZEISS MEDITEC AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 80,6 €
Spread / Average Target -8,5%
EPS Revisions
Managers
NameTitle
Ludwin Monz President & Chief Executive Officer
Michael Kaschke Chairman-Supervisory Board
Justus Felix Wehmer Chief Financial Officer
Markus Guthoff Member-Supervisory Board
Cornelia Grandy Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
CARL ZEISS MEDITEC AG28.99%8 827
THERMO FISHER SCIENTIFIC21.10%108 715
DANAHER CORPORATION27.65%94 532
INTUITIVE SURGICAL-0.50%55 015
BOSTON SCIENTIFIC CORPORATION6.93%53 498
ILLUMINA3.01%45 930